Trillium Therapeutics Inc. (NASDAQ/TSX:TRIL) is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. We have a strong focus on CD47, a molecule that tumors frequently use to evade the immune system. CD47 is a protective ᅢᄁ¬ツᆲᅤモdo not eatᅢᄁ¬ツᆲᅡン signal that blocks the ability of certain immune cells to destroy the tumor. By blocking this ᅢᄁ¬ツᆲᅤモdo not eatᅢᄁ¬ツᆲᅡン signal with decoy receptors, we aim to unmask tumor cells and make them visible to, and eradicated by, the immune system.